Questions before the purchase
The OkuStim device uses a weak electrical current to stimulate the eyes. This happens via the OkuEl electrodes, which are held on the surface of the eye with the help of the OkuSpex frame. The stimulation takes place with closed eyes. The therapy parameters are determined and set by the doctor beforehand.
Click here to learn more.
The therapy with OkuStim offers the chance to slow down the course of the disease. This can present itself in:
- Slowing down the progression of visual field loss
- Improvement of the cellular activity. Cellular activity is measured by means of an electroretinogram (ERG). An increased cellular activity means, among other things, an enhanced reaction of the cells to light stimuli. This can meanthat a greater number of cells is involved in the visual impression, which in turn can have a positive effect on the visual field.
- Improvement of visual acuity
As with all therapies and medicines, different patients may benefit differently from the TES therapy with the OkuStim system.
The therapy is applied once a week for 30 minutes. This therapy aims to slow down the progression of the disease, therefore it is a permanent therapy. The duration depends on its apparent benefit.
Research has shown that electrical stimulation with weak currents can activate signaling pathways the in affected retina that have a protective effect on retinal cells. This neuroprotective effect can delay retinal degeneration and preserve the function of the remaining cells.
The aim of the therapy is to maintain cellular activity. This is only possible if the visual cells still have a residual function. Therefore, one should commence the therapy as early as possible after the onset of retinitis pigmentosa. The therapy is out of the question, however, if growth processes are active in the eye (such as macular edema). Please contact one of the competence centres for a personal examination and consultation.
Data and results are only available for retinitis pigmentosa.
Treatment of other hereditary retinal dystrophies such as cone rod dystrophy, choroideremia or Usher syndrome is possible.
Future studies will be required to evaluate the effectiveness of the OkuStim System in other eye diseases such as AMD and Stargardt's disease.
In studies the therapy has only been used with adult patients. There is no data available for underage patients.
The costs for the therapy and the OkuStim products have to be borne by the patient. However, reimbursement by the health insurance can be requested on an individual case basis. This may vary by country.
Yes, the OkuStim products are only available on prescription. They are available through one of our distribution partners upon presentation of the original prescription.